Previous 10 | Next 10 |
2024-01-23 01:59:00 ET Eli Lilly (NYSE: LLY) is a highly successful business, and as with any big corporate success story, some critics will offer a counter-narrative of stagnation and decay lurking in the background. However, frequently enough, such bearish overtures are missing ke...
2024-01-22 09:15:00 ET Summary Novo Nordisk's weight loss drug, Wegovy, earned $1.38 billion last quarter and is projected to share a large piece of the growing weight-loss drug market. Despite its market dominance, Novo faces challenges in affordability, competition (like Eli Lil...
2024-01-22 08:50:51 ET Summary Positive preliminary results were achieved in early-stage studies of its protein degraders, NX-2127 and NX-5948, for the treatment of B-cell malignancies. Protein degradation platform offers several advantages over other BTK drugs, such as ability to...
2024-01-22 00:41:37 ET Summary I opine RMD is now attractively valued given its long-term stability and its product is highly demanded. ResMed's product is in high demand in the modern obesity epidemic. A new weight loss drug will have little effect on the Company. ...
2024-01-21 23:13:06 ET Summary The Healthcare sector shows promising growth opportunities in 2024, with an aging population and increased demand for improved healthcare. The cell and gene therapy industry is expected to grow at a compound annual growth rate of 34% from 2021-2027. ...
2024-01-21 12:00:01 ET More on Intuitive Surgical, J&J, etc. Medtronic: Hugo's Global Rollout Is Positive; GLP-1 Is Negative Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuit...
2024-01-21 11:02:00 ET The healthcare sector is home to many excellent, innovative corporations that have made many investors richer. However, no healthcare company has reached a market capitalization of $1 trillion. Perhaps that's not so surprising. After all, very few companies are part o...
2024-01-21 02:50:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended December 31, 2023, Baron Health Care Fund® (the Fund) advanc...
2024-01-20 16:29:00 ET With shares of Eli Lilly (NYSE: LLY) gaining an impressive 59% in 2023, it's no secret investors are eager to learn what the company is aiming for in 2024. Happily, there are quite a few clues about what's coming next, including from senior management, and...
2024-01-20 09:45:00 ET Eli Lilly (NYSE: LLY) and Meta Platforms (NASDAQ: META) don't seem to have much in common as they operate entirely different businesses in completely different industries. The former is a leader in the biotech industry, while the latter is a social med...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 07:07:00 ET If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the...
2024-07-30 05:48:00 ET Going into 2024, DexCom 's (NASDAQ: DXCM) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes. However, last week was the worst for De...
2024-07-29 15:13:21 ET Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding th...